We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+9.7%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$300M
Cap. Flow
+$374M
Cap. Flow %
23.51%
Top 10 Hldgs %
49.78%
Holding
111
New
24
Increased
22
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$67.1M
2
NVCR icon
NovoCure
NVCR
+$58M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.1M
4
AZN icon
AstraZeneca
AZN
+$28.6M
5
IART icon
Integra LifeSciences
IART
+$27.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$35.3M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$33.2M
3
RVMD icon
Revolution Medicines
RVMD
+$25.4M
4
TXG icon
10x Genomics
TXG
+$21.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$270M 16.98%
3,000,000
+2,100,000
+233% +$203M
NVCR icon
2
NovoCure
NVCR
$2.04B
$81.6M 5.13%
+2,739,704
New +$58M
TGTX icon
3
TG Therapeutics
TGTX
$8.58B
$80.7M 5.07%
2,681,242
+146,702
+6% +$4.21M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.5B
$65.8M 4.14%
+1,001,400
New +$67.1M
KRYS icon
5
Krystal Biotech
KRYS
$9.88B
$56.1M 3.53%
358,379
+141,400
+65% +$25.1M
GRFS
6
Grifois
GRFS
$5.16B
$49.1M 3.09%
6,605,425
+2,083,722
+46% +$17.4M
AXGN icon
7
Axogen
AXGN
$2.1B
$48.7M 3.06%
2,955,943
-50,000
-2% -$708K
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.23B
$48.5M 3.05%
6,560,000
-1,968,500
-23% -$18.2M
TEVA icon
9
Teva Pharmaceuticals
TEVA
$35.9B
$46.1M 2.9%
+2,093,000
New +$38.1M
TERN
10
DELISTED
Terns Pharmaceuticals
TERN
$45.1M 2.83%
8,142,500
+1,918,956
+31% +$13M
ORGO icon
11
Organogenesis Holdings
ORGO
$308M
$40M 2.51%
12,484,876
+645,000
+5% +$2.16M
NRIX icon
12
Nurix Therapeutics
NRIX
$2.43B
$39.6M 2.49%
2,102,833
+1,036,999
+97% +$23.8M
UTHR icon
13
United Therapeutics
UTHR
$26.3B
$38.6M 2.43%
109,394
+7,500
+7% +$2.76M
CELC icon
14
Celcuity
CELC
$4.03B
$33.6M 2.11%
2,565,087
+1,319,700
+106% +$18.6M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.84B
$32.9M 2.07%
2,492,000
+1,401,016
+128% +$24M
JSPR icon
16
Jasper Therapeutics
JSPR
$22.9M
$32M 2.01%
1,494,420
+150,755
+11% +$3.14M
IART icon
17
Integra LifeSciences
IART
$1.54B
$28.9M 1.82%
+1,276,000
New +$27.9M
NPCE icon
18
Neuropace
NPCE
$505M
$27.2M 1.71%
2,433,168
– –
AZN icon
19
AstraZeneca
AZN
$263B
$26.8M 1.68%
+204,500
New +$28.6M
CCCC icon
20
C4 Therapeutics
CCCC
$376M
$25.1M 1.58%
6,978,942
+374,946
+6% +$1.86M
QDEL icon
21
QuidelOrtho
QDEL
$1.09B
$24.4M 1.53%
547,082
-138,918
-20% -$5.68M
INSM icon
22
Insmed
INSM
$23.2B
$22.1M 1.39%
320,272
+290,000
+958% +$20.9M
IKT icon
23
Inhibikase Therapeutics
IKT
$366M
$20.6M 1.29%
+6,325,000
New +$15.8M
ASND icon
24
Ascendis Pharma A/S
ASND
$16.7B
$19.8M 1.25%
+144,000
New +$18.9M
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$680M
$19M 1.2%
1,130,679
+195,891
+21% +$3.76M
1
2 3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Soleus Capital Management held 111 positions worth $1.59B, up 23% from $1.29B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management deployed $374M of net new capital in Q4 2024, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $25.4M trimmed.

  • Soleus Capital Management's largest Q4 2024 buy was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.
  • Soleus Capital Management added most to Krystal Biotech in Q4 2024, an estimated $25.1M increase.
  • Soleus Capital Management's biggest Q4 2024 reduction was Revolution Medicines, cutting an estimated $25.4M.
  • Soleus Capital Management fully exited Sanofi in Q4 2024, selling an estimated $35.3M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $1.59B portfolio in Q4 2024.
  • Soleus Capital Management opened 24 new positions and closed 30 in Q4 2024.
  • Soleus Capital Management's portfolio value rose 23% quarter-over-quarter to $1.59B.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.